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Inositols (myo-inositol and inositol hexakisphosphate) exert a wide range of critical activities in both physiological and pathological
settings.Deregulated inositolmetabolismhas been recorded in a number of diseases, including cancer, where inositolmodulates dif-
ferent critical pathways. Inositols inhibit pRB phosphorylation, fostering the pRB/E2F complexes formation and blocking progres-
sion along the cell cycle. Inositols reduce PI3K levels, thus counteracting the activation of the PKC/RAS/ERK pathway downstream
of PI3K activation.Upstreamof that pathway, inositols disrupt the ligand interaction between FGF and its receptor aswell aswith the
EGF-transduction processes involving IGF-II receptor and AP-1 complexes. Additionally, Akt activation is severely impaired upon
inositol addition. Downregulation of both Akt and ERK leads consequently to NF-kB inhibition and reduced expression of inflam-
matory markers (COX-2 and PGE2). Remarkably, inositol-induced downregulation of presenilin-1 interferes with the epithelial-
mesenchymal transition and reduces Wnt-activation, 𝛽-catenin translocation, Notch-1, N-cadherin, and SNAI1 release. Inositols
interfere also with the cytoskeleton by upregulating Focal Adhesion Kinase and E-cadherin and decreasing Fascin and Cofilin, two
main components of pseudopodia, leading hence to invasiveness impairment.This effect is reinforced by the inositol-induced inhi-
bition on metalloproteinases and ROCK1/2 release. Overall, these effects enable inositols to remodel the cytoskeleton architecture.
1. Introduction
Inositol (myo-Ins) and its phosphate metabolites exert a wide
range of critical activities in both physiological and patholog-
ical settings. Indeed, deregulation of inositol metabolism has
been extensively investigated in several illnesses, including
neurological disorders [1], polycystic ovary syndrome [2],
and metabolic diseases [3].
In thewake of the renewed interest for inositol phosphates
(InsPs) and other inositol-based compounds, studies on
the anticancer properties of both inositol hexakisphosphate
(InsP6) and myo-Ins have gained momentum during the
last decades. InsP6 inhibits growth and invasiveness of a
number of cancer types, while both InsP6 and myo-Ins have
been demonstrated to display significant chemopreventive
effects both in vitro and in vivo. Furthermore, inositols have
been involved in modulating unexpected processes, includ-
ing mRNA transcription, chromatin remodeling, cytoskele-
ton configuration, and p53 activity, just to mention a few.
Therefore, these new findings prompted reassessing under
a new light the putative role of both myo-Ins and InsP6 in
carcinogenesis.
2. Epidemiology: Diet and Cancer
Since the early eighties [4], it has been recognized that
wide variation in cancer incidence among different countries
around the world can primarily be ascribed to environmental
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factors, among which diet is likely the most important [5].
This evidence is very strong for some cancers, like breast,
prostate, and colon tumors, where differences in tumor
incidence across countries have beenmainly ascribed to their
respective dietary habits [6]. Those data provided the ratio-
nale for the so-called “fiber hypotheses” [7], for which grains
refining and lack of dietary fiber may have a “causative” role
in colon and breast carcinogenesis [8]. Several investigations
led support to this hypothesis [9], even if some inconsisten-
cies have been recorded [10]. Yet, such association is probably
a too simplistic one, given that fibers could not be the sole
putative preventive factor. Indeed, colon cancer incidence has
been shown to differ significantly among groups consuming
approximately the same amount of fibers [11]. These findings
indicate that to assess the correlation between diet and
cancer properly we should evaluate the consumption of
specific components rather than focusing on the overall fiber
intake. Both epidemiological and molecular investigations
have indeed provided valuable data suggesting that distinct
dietary components may exert specific anticancer activities.
Among those nutrients, compelling evidence gathered to
date has evidenced that lignans, polyphenolic acids, stilbenes,
bioflavonoids, phytic acid, and inositols exert unquestionable
anticancer effects [12, 13]. Moreover, it has been observed that
only the consumption of fibers with high content of phytic
acid is inversely correlated with colon cancer [14].
3. Inositol and Inositol Hexakisphosphate
InsP6 is contained mainly in cereals, legumes, and oilseed
[15]. The presence of a phosphate group in positions 1, 2, and
3 (axial-equatorial axis) confers unique properties to it as this
configuration provides a specific chelating capacity regarding
polyvalent cations, including iron and other potentially
toxic elements (Ni, Zn, Cu, and even Uranium) [16, 17].
This property makes InsP6 an excellent chelator of many
potentially harmful trace elements that have been shown to
cause deleterious effects in humans [18]. Moreover, InsP6
capacity in blocking hydroxyl radical formationmakes phytic
acid a strong physiological antioxidant [19]. Insofar as InsP6
is often referred to as an antinutrient [20] responsible for iron
deficiencies mostly in underdeveloped countries, it should be
emphasized that InsP6 displays its antinutritional effects only
when the diet is already deprived of trace elements [21].
Dietary InsP6 is mainly digested in the gut by bacterial
phytases and phosphatase [22], thus releasing myo-Ins and
other inositol phosphates (InsPs). Yet, a variable fraction of
dietary IP6 is directly absorbed as such and can be recovered
in plasma and urine [23], even if this assumption has been
subject of controversy [24, 25].
A mixed western diet provides the human adult with
approximately 1 g of total inositol per day [26]. No require-
ment for dietary inositol in man has been determined, even
if physiological needs could be highly variable depending
on the person’s age, the long-term use of antibiotics, or the
regular consumption of coffee [27]. How appropriate the
bioavailability of myo-Ins and InsP6 in western alimentary
regimens is still constitutes amatter of debate [28, 29]. By con-
sidering that from the ‘70s many foods have been processed
to remove phytic acid (owing to its alleged antinutritional
effects) it may be surmised that in western countries low-
vegetable consumers may suffer from a relative deficiency of
myo-Ins due to the reduced content of both myo-Ins and
phytic acid in the diet. Furthermore, assessment of myo-
Ins requirements is further complicated by the fact that a
significant amount of inositol is endogenously synthesized
from glucose. Glucose-6-phosphate is isomerized by D-3-
myo-inositol-phosphate synthase (MIPS1 encoded by the
ISYNA1 gene) to yield inositol-3-phosphate (Ins3P) and then
converted by inositol monophosphatase-1 (IMPA-1) into free
myo-Ins [30]. Both enzymes are inducible in response to the
specific tissue requirements, thus explaining why myo-Ins
concentrations differ so greatly among different tissues and
physiological conditions [31].
After cellular internalization through endocytosis InsP6
is partially dephosphorylated yieldingmyo-inositol and inos-
itol phosphates, mainly InsP5 [32]. However, free myo-Ins is
actively transported into cells by a means of complex trans-
port system. Within cells myo-Ins is converted into inositol
phospholipids (phosphatidylinositol, PI, and phosphatidyli-
nositol phosphate(s), PIP(s)), inositol-glycans (IPGs), inos-
itol phosphates (InsPs, including InsP6), and pyrophos-
phates (PP-IPs), according to a complex network extensively
reviewed elsewhere [33, 34].
4. Molecular Mechanisms of Action
4.1. Cell Cycle Control and Apoptosis. Several studies have
investigated the inhibitory activity of InsP6 on cancer cells
from both animals and humans. Results are unambiguous
and show that InsP6 induces G1 phase arrest and abridges
S phase of cancer cells, mainly by modulation of cyclins,
upregulation of p53, p57, p27Kip1, and p21WAF/CIP1, and down-
regulation of phosphorylated pRb [35–37].The family of pRB
subunits (pRB/p107 and pRB2/p130) inhibits the cell cycle
progression by forming complexes with E2F in the G0 phase.
InsP6, by increasing the hypophosphorylated form of pRB,
increases the pRB/E2F complexes formation, thus blocking
further progression along the cell cycle [38]. Consequently,
in InsP6-treated cancer cells, a significant downregulation of
genes involved in cell cycle advancement (like c-myc, cyclin
H, and FUSE) and an upregulation of those activated during
cycle inhibition (CSK2, p57, and Id-2) have been observed
[38]. Inhibition of breast cancer cell proliferation occurs
independently from the estrogen receptor (ER) status, as it
was achieved in both ER negative (MDA-MB-231) and pos-
itive (MCF-7) cells [39]. Similar results have been obtained
in other cancers, even though subtle differences have been
recorded among different cell lines [40, 41]. For instance,
when leukemia cells were treated with InsP6, only some cell
lines (A230 and K562) were arrested in G2/M phase, while
other cell lines (including CD34+ from myelogenous leuke-
mia patients) were committed to apoptosis [42]. Early studies
have suggested that InsP6 effect is rather cytostatic than cyto-
toxic [43, 44]. However, further investigation demonstrated
that InsP6 had unequivocal apoptotic effects on both solid
and haematogenous tumors. Indeed, InsP6 has been shown
to trigger programmed cell death both in vitro and in vivo
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[45] in numerous cancer cell lines including Kaposi’s sarcoma
[46] and prostate, breast, cervical, pancreas, melanoma [47],
and colon cancer [48–50]. This apoptotic effect is frequently
associated with growth inhibition [35, 51] and ascertaining
whether both effects occur independently from each other
still needs to be investigated. Additionally, InsP6 has been
shown to synergize with both doxorubicin and tamoxifen
in inhibiting breast cancer growth, namely, in drug-resistant
cancer cell lines [52]. This result implies that InsP6 may
counteract drug resistance frequently displayed by tumor
cells and should therefore be considered a useful adjunct in
delivering conventional anticancer drugs. On the contrary,
myo-Ins has been shown to have only aminimal proapoptotic
activity and to induce a mild decrease in growth proliferation
in colon, breast, soft tissue, and lung tumors [53]. Yet, myo-
Ins is able to significantly synergize with InsP6, both in vitro
and in vivo, in inducing cancer inhibition [54].
However, some results hint at a more subtle and complex
role for inositol and its phosphate derivatives. In some
circumstances, instead of apoptosis or growth inhibition,
cell differentiation occurs after InsP6 treatment. Induction
of differentiation in human erythroleukemia cells was pre-
liminarily evidenced following InsP6 and subsequently in
several other cancers, including rhabdomyosarcoma and
breast, colon, and prostate tumors [55–57]. Why cancer
cells respond so differently following InsP6 administration is
poorly understood. It can be hypothesized that other factors,
namely, other inositol phosphate derivatives, may participate
in such processes, thereby driving the final output into diverse
fates [58]. Yet, the contribution of context-dependent cues in
modulating InsP6 effects cannot be discarded.
4.2. The p53 Network. Inhibition of cell proliferation and
induction of apoptosis have been recorded in numerous
cancer cell lines after InsP6 treatment. A crucial factor in both
issues is represented by p53 activity and the subsequent selec-
tive pathways triggered downstream of p53. InsP6 increases
p53 levels severalfold at both mRNA and protein levels [47,
59]. However, consistent data suggest that p53 is not manda-
tory for triggering InsP6-related effects, as apoptosis and
inhibition of cell growth have been both observed in cancer
cells lacking p53 [60]. On the contrary, p27 and p21 should be
considered as essential molecular target of InsP6, given that
the simultaneous knockdown of both p21 and p27 completely
abrogates the anticancer effects of InsP6 [51]. By analogy,
myo-Ins has been proven to reduce lung cancer incidence
in mouse lacking p53 and treated with N-nitrosomethylurea
[61]. Yet, a very recent paper demonstrated that oral myo-
Ins does not suppress cancer development in p53 knockout
mice [62], while evidence about the proapoptotic effect of
myo-inositol is still inconclusive even in presence of p53.
Thereby the question is still open and further studies are
warranted to understand whether p53 activity is effectively
required in mediating anticancer effects displayed by both
InsP6 and myo-Ins. Downstream of p53 InsP6 has been
demonstrated to reduce prosurvival factors and to upregulate
caspases and other components of the proapoptotic BCL-
2 family [63–66]. Furthermore, InsP6 has been shown to
inhibit NF-kB activity in different cancers [67, 68]. NF-kB is
a pivotal factor involved in fostering both survival pathways
and the epithelial-mesenchymal transition (EMT).Therefore,
targeting NF-kB is currently deemed a promising approach
in cancer management. In prostate carcinoma, constitutive
activation of NF-kB is inhibited by InsP6 [69], while in HeLa
cells phytic acid prevents nuclear translocation of NF-kB and
NF-kB-luciferase transcription activity [49]. In Caco-2 colon
cancer cells, InsP6-mediated NF-kB inhibition is likely to
occur through the block of the p65 subunit of NF-kB and its
inhibitor IkBa [50].
As observed with other natural compounds (grape seed
extracts, melatonin), the apoptotic effect triggered by inositol
derivatives seems to be specific for cancer cells, given that
both InsP6 andmyo-Ins did not promote apoptosis in normal
cells. Moreover, a “paradoxical” antiapoptotic effect of InsP6
has been noticed in normal cells exposed to iron-induced
apoptosis [70]. Therefore, why normal and cancerous cells
respond differently to both InsP6 and myo-inositol still
deserves to be explained in detail.
4.3. Inhibition of the PI3K/Akt Pathway. The PI3K/Akt path-
way is undoubtedly a pivotal hub upstream the activation of
survival pathways, including the activation ofWnt andNF-kB
[71]. PI3K triggers activation of Akt kinases through direct
binding to the pleckstrin homology domain and the sub-
sequent phosphorylation of Akt at two conserved residues.
Hence, activated Akt modulates the function of numerous
substrates involved in the regulation of cell survival, cell
cycle progression, and cellular growth, eventually enabling
cancer cells to become more aggressive [72]. These findings
make the PI3K/Akt pathway one of the most attractive
targets for therapeutic intervention. It is therefore worth
noting that both InsP6 and myo-Ins significantly reduce
PI3K expression (at both mRNA and protein levels) [73]
and Akt activation by inhibiting its phosphorylation [74, 75].
InsP6 impairs directly PI3K activity and thus the PI3K-
dependent activation of the tumor promoter-induced AP-
1, as well as the phosphorylation-dependent activation of
ERK [75]. Inhibition of PI3K activity and subsequent block-
ing of PKC and mitogen-activated kinases (MAPK) have
been so far documented by several in vitro [76–78] and in
vivo chemopreventive studies [79, 80]. Additionally, InsP6
interacts with clathrin-associated protein complex-2 and
inhibits PI3K, ERK, and MAPK activation, thus impairing
ErbB1 endocytosis and ligand-induced Shc phosphorylation
[81]. Given that PI3K/Akt pathway activity is mandatorily
required for triggering EMT, blocking PI3K would hinder
the transformation of cancer cells into a more aggressive
phenotype. Indeed, breast cancer cells treated in vitro with
myo-Ins showed increased E-cadherin, downregulation of
metalloproteinase-9, and redistribution of 𝛽-catenin behind
cell membrane, while motility and invading capacity were
severely inhibited [75]. Those changes were associated with
a significant downregulation of PI3K/Akt activity, leading to
a decrease in downstream signaling effectors: NF-kB, COX-
2, and SNAI1.Moreover, myo-Ins decreases presenilin-1 (PS1)
levels and inhibits its activity, thus leading to lowered Notch-
1 release and SNAI1 levels. Furthermore, inositol-treated cells
underwent profound cytoskeleton remodeling [75]. Overall,
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these data indicated that myo-Ins inhibits the principal
molecular pathway supporting EMT in cancer cells.
4.4. Inhibition of Invasiveness and Motility. The ability of
cancer to metastasize relies primarily on the invasiveness and
increased motility of tumor cells. It is therefore worth noting
that, by blocking EMT, myo-Ins significantly hampers both
motility and invasiveness of breast cancer cells. This effect
is likely to be ascribed to cytoskeleton remodeling and to
the concomitant inhibition of metalloproteinases (MMPs)
release [75]. Similarly, InsP6 significantly reduces the number
of lung metastatic colonies in a mouse metastatic tumor
model [82], while in MDA-MB-231 breast cancer cells this
effect is mediated by reduced adhesion and MMPs release
[83, 84].
4.5. Wnt Signaling and Anti-Inflammatory Effects. Activation
of the Wnt/𝛽-catenin pathway occurs in several cancers.
Overexpression of the Wnt ligand, usually in association
with deregulated 𝛾-secretase activity, may lead to deregulated
expression and redistribution of 𝛽-catenin and of several
molecular factors belonging to the so-called inflammatory
pathway, like COX-2 and PGE2 [85]. Increased expression
of the aforementioned molecules has been demonstrated
to be associated with carcinogenesis in numerous tissues,
chiefly in colon cancer [86]. It is of high relevance that InsP6
downregulates both in vitro and in vivo the Wnt pathway
via 𝛽-catenin inhibition, thus significantly reducing COX-
2 at both the mRNA and protein levels [87]. Eventually,
this study demonstrated that InsP6 administration markedly
suppressed in a dose-dependent manner the incidence of
cancer in male Sprague Dawley rats when compared to con-
trols. Moreover, InsP6 counteracts the proliferative response
following inflammatory injury by inhibiting cyclin D1 and
histone H3 expression [88].
In breast cancer cells, myo-Ins has been proven to
downregulate both NF-kB and COX-2, while relocating 𝛽-
catenin behind cellmembrane [76]. Such inhibitory effects on
inflammatory markers may not be confined to epithelial cells
but should also probably involve the surrounding microen-
vironment. Indeed, both InsP6 and myo-Ins have been
demonstrated to prevent pulmonary fibrosis, breast density,
and chronic inflammatory damage, likely by influencing the
crosstalk among cells and their milieu [89–91]. Given that
TGF𝛽-1 released by both fibroblasts and epithelial cells is a
profibrogenic factor regulating the balance between matrix-
degrading metalloproteinases and their inhibitors [92], it
is quite exciting that myo-Ins has been demonstrated to
modulate the expression of both TGF𝛽 and its receptors.
Indeed, myo-Ins mitigates colonic epithelium inflammation
as well as inflammatory consequences on colon stromal cells
during microbial infections [93, 94]. Furthermore, InsP6 has
been shown to exert valuable effects onfibroblasts by blocking
the syndecan-4 dependent focal adhesion and microfilament
bound [95]. Syndecan-4 is a heparan sulphate proteoglycan
embedded into cellular membranes, where it regulates cell-
matrix interactions by interfering with cytoskeleton proteins
and integrins. Indeed, in human mammary cancer cell lines,
cell adhesion to extracellular matrix was decreased after
InsP6 treatment [84]. Moreover, syndecan binds to the
fibroblast growth factor (FGF), fostering its coupling with the
FGF receptor. InsP6 disrupts such interaction, thus inhibiting
the FGF-based signaling [96]. Inositol-related effects on
the cell milieu also involve modulation of angiogenesis.
Formation of new blood vessels is required for sustaining
cancer growth and invasiveness. Disruption of the structural
relationships among cancer cells and theirmicroenvironment
promotes neoangiogenesis, mainly through the release of
vascular endothelial growth factor (VEGF). InsP6 negatively
modulates VEGF release from tumor cells [45] and impairs
endothelial cells growth [97]. Likely, VEGF reduced synthesis
may be due to InsP6-mediated inhibition on PI3K/Akt and
MAPK/ERK pathways [82], given that both of them are
deemed to modulate VEGF upregulation [98, 99]. Addition-
ally, the synergistic activity of hypoxia and IGF-II increases
VEGFmRNA expression and upregulates HIG-1 protein that,
in turn, reinforces VEGF release [100]. Given that InsP6 has
been shown to antagonize IGF-II activity by inhibiting the
IGF-II receptor binding [101], it is likely that some InsP6
antiangiogenic effects can be ascribed to this mechanism.
Overall, these data suggest that inositol and its phosphate
derivatives exert complex biological functions involving both
cells and stromal factors. Yet, given the entrenched correla-
tions occurring among cells and microenvironment during
carcinogenesis [102, 103] the stromal effects of both InsP6 and
myo-Ins deserve to be still fully investigated.
4.6. Anticancer Activity through Insulin Modulation. Myo-
inositol and its isomer D-chiro-inositol (D-chiro-Ins) partic-
ipate in both insulin and glucose metabolisms, and deregu-
lated myo-Ins metabolism has been documented in several
conditions associated with diabetes or insulin resistance
[3]. Indeed, low levels of inositol have been observed in
biological fluids and insulin target tissues (muscle, liver,
and fat), frequently associated with excessive myo-Ins renal
excretion, while low intracellular levels of myo-Ins have been
detected in insulin insensitive tissues [104]. When insulin
binds to its receptor, two distinct inositol-phosphoglycans
(IPGs), incorporating either myo-Ins or D-Chiro-Ins (IPG-
A and IPG-P), are released by insulin-stimulated hydrol-
ysis of glycosyl-phosphatidylinositol lipids located on the
outer leaflet of the cell membrane. IPGs affect intracellular
metabolic processes, namely, by activating key enzymes
controlling the oxidative and nonoxidative metabolism of
glucose and acting as insulin-mimetic when administered in
vivo in normal or diabetic rats [105]. Glycan derivatives of
inositol significantly reduce insulin resistance and promote
appropriate glucose metabolism [106]. Given that myo-Ins
may efficiently counteract insulin resistance and itsmetabolic
complications [107], it is tempting to speculate that it may
also prevent IGF-1 increase associated with insulin resistance.
As both insulin resistance and IGF-1 are linked to increased
cancer risk [108], it is conceivable that myo-Ins modulation
of insulin activity may efficiently contribute to reducing
cancer risk. Indeed, InsP6 has been already shown to inhibit
the IGF-1 receptor pathway-mediated sustained growth in
cancer cells [85]. Moreover, cancer cells are featured by
a glycolytic metabolomic fingerprint, thought to confer a
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“proliferative advantage” during the neoplastic development
[109]. It is therefore tempting to speculate if inositol addition
can antagonize cancer development by normalizing glucose
metabolism in cancer cells, another matter that eventually
still needs to be fully investigated.
4.7. Antioxidant and Other Effects. Myo-Ins displays a mod-
erate antioxidant activity, while InsP6 is among the strongest
antioxidants present in nature. By chelating polyvalent
cations, InsP6 and myo-Ins suppress Fenton’s reaction and
the consequent release of hydroxyl radicals [110]. In biological
tissues InsP6 has been shown to inhibit xanthine oxidase [111]
and reactive oxygen species production, thus dramatically
inhibiting the free radical-based damage occurring in cells
and tissues following inflammation, hypoxia, or exposition to
radiation injury [91, 112, 113]. Myo-Ins counteracts oxidative
damage in fish exposed to environmental stresses [114] and
significantly inhibits systemic markers of oxidative stress
in gynecological patients [115]. InsP6 scavenges superoxide
radicals in vitro and in vivo, thus preventing formation of
ADP-iron-oxygen complexes that trigger lipid peroxidation
[116]. Indeed, inhibition of lipid peroxidation has been
documented in animals after InsP6 administration [117, 118].
As increases in both ROS and lipid peroxidation have been
associatedwith cancer development, it has been hypothesized
that some anticancer chemopreventive effects displayed by
InsP6 and myo-Ins could therefore be ascribed to their
antioxidant capability. However, as recorded for other natural
compounds, the antioxidant property of inositol is strictly
context-dependent as, under specific conditions, both myo-
Ins and InsP6 may increase free radical production [119].
5. Effects on the Immune Function
Even if it is still limited, current evidence suggests that inosi-
tols may play an appreciable regulatory activity on immune
function in vitro and in vivo. Inositol hexakisphosphate
and myo-Ins enhance NK activity in mice treated with 1,2-
dimethylhydrazine (DMH), a colon carcinogen, which also
significantly reduces NK function [120, 121]. In this model,
InsP6 also reverses tumor induction, decreases cancer-related
death, and specifically boosts NK cytotoxicity in a dose-
dependent manner. As previously observed in other studies,
the association of InsP6 and myo-Ins displays synergistic
effects, given that significantly better results were observed in
animals treated with a combination of both [120]. InsP6 acts
as a neutrophil priming agent and it upregulates several neu-
trophil functions, including enhancing superoxide produc-
tion and phagocytosis [119]. Additionally, InsP6 modulates
a number of inflammatory markers, namely, involving IL-8
release by stimulated neutrophils [119]. InsP6 also modulates
the transcription genes for TNF by decreasing it and its
receptors in colon cancer cells [122]. This downregulating
effect of InsP6 on inflammatory processes is mirrored by
the aforementioned inhibitory activity displayed by myo-Ins
on several inflammatory pathways (COX-2 and PGE2) [76].
Therefore, it seems that both inositols exert inhibitory control
on the activation of the inflammatory pathways, which are
frequently upregulated during carcinogenesis.
6. Chemopreventive and Therapeutic
Efficacy in Animal Studies
The chemopreventive as well as the therapeutic activity in
vivo of InsP6 has been documented by an impressive body
of studies. Exogenous administration of InsP6 in drinking
water, one or twoweeks after azoxymethane induced carcino-
genesis, prevents the onset of colon cancer in Fisher rats [123].
Preventive activity was also observed when InsP6 was added
in higher concentration 5 months later after the carcinogenic
stimulation [124]. Inositol hexakisphosphate can indeed pre-
vent even the formation of aberrant colon crypts, thought to
be the histological precursor of the neoplastic transformation
[125].
On the other hand, inositol hexakisphosphatemay poten-
tiate the anticancer effects of conventional chemotherapy in
preventing the successful development of cancer implants.
Indeed, the administration of liposomes containing both
InsP6 and irinotecan (CPT-11) showed higher efficacy in
inhibiting the viability and the growth of colon tumor
xenografts in mouse when compared to single compounds
alone [126]. InsP6 chemopreventive activity is not restricted
to the gastrointestinal tract, as it has been shown that inositols
may efficiently counteract the carcinogenic effect of chemi-
cals on breast tissue. Breast tumor incidence after exposure to
7,12-dimethylbenz[a]anthracene or N-methylnitrosourea is
significantly reduced in animals treated with InsP6. Similarly,
InsP6 dramatically reduces by almost 64% the burden of
implanted DU-145 prostate cancer [35] as well as the growth
of transgenic adenocarcinoma of the prostate in mouse [127,
128]. Similarly, inositol hexakisphosphate inhibits growth
and induces G1 arrest and apoptotic death of androgen-
dependent human prostate carcinoma LNCaP cells [40].
Namely, in a transgenic mouse model of prostate carcinoma
(TRAMP), orally administered InsP6 has been able to inhibit
cancer progression at prostatic intraepithelial neoplasia stage
and strongly reduced the incidence of adenocarcinoma (pro-
static intraepithelial neoplasia/adenocarcinoma, 75 : 25% in
the InsP6 group versus 39 : 61% in the control group) [127].
These findings evidence the chemopreventive efficacy of oral
administered InsP6 in vivo as well as its safety.
Additionally, InsP6 or myo-Ins has been shown to induce
the regression of other different types of cancer, like rhab-
domyosarcoma, liver cancer [129], soft tissue [130], and
fibrosarcoma [43, 83, 131]. Skin tumorigenesis induced by
chemical compounds [44] or by physical factors (i.e., UVB)
[68] was also demonstrated to be significantly diminished
by InsP6 administration. Both InsP6 and myo-Ins reduced
the incidence and growth of lung tumors chemically induced
in mice [132]. Indeed, dietary inositol has been shown to
inhibit lung tumorigenesis in female A/J mice exposed to
the carcinogen benzo(𝛼)-pyrene or 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanone: myo-Ins was also effective in the
postinitiation phase and when given for short periods of time
before, during, and immediately after carcinogen exposure
[133, 134]. Overall, myo-Ins anticancer efficacy was proven to
be lower when compared to InsP6. However, it is noticeable
that myo-Ins potentiates significantly the antitumor effects
displayed by InsP6 in vivo [135, 136].
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7. Chemopreventive and Therapeutic
Efficacy in Human Clinical Trials
Both myo-Ins and InsP6 are safe, even when administered at
high doses, as assessed by several clinical trials performed in
cancer patients as well as in humans suffering from other dis-
eases (mostly with gynecological diseases like PCOS). Mild
side effects (mostly represented by nausea or diarrhea) are
reported in a small fraction of subjects, only for doses up to
12 g/day (reviewed in [137]).
On the other hand, InsP6 has been demonstrated to exert
valuable anticancer effects even in vivowhen administered to
cancer patients. An antitumor activity has been observed in
advanced colon cancer patients, where InsP6 plus myo-Ins
treatment is associated with appreciable reduction in tumor
burden and improved quality of life. Moreover, if inositols
were added along with conventional chemotherapy, colon
cancer patients experienced significantly less side effects than
controls, as reported in a pilot study [138]. Furthermore,
prolonged survival and better quality of life have been
obtained in some anecdotal cases of breast and lung cancer
patients treated with InsP6 and myo-Ins [139–141]. Again, in
a prospective, randomized study, InsP6 and myo-Ins ame-
liorate the responsiveness to chemotherapy in breast cancer
patients andmarkedly reduce the burden of side effects [142].
As previously noticed in animal studies, myo-Ins has been
demonstrated to exert a significant chemopreventive activity
also in human beings [143]. A study enrolling 26 smokers
showed that myo-Ins in a daily dose up to 18 g/p.o. is safe
and well tolerated, while inducing a significant regression of
individual pulmonary dysplastic lesions (91% in the inositol-
treated group versus 48% in control group) in a sample of
heavy smoker individuals [144]. A significant increase in a
genomic signature of PI3K pathway activation has been doc-
umented in the cells of the bronchial airway of patients with
dysplastic lesions, thus suggesting that PI3K is activated in the
proximal airway before tumorigenesis. Treatment with myo-
Ins is able to induce a marked regression of both dysplastic
lesions and PI3K activity. Such preliminary findings have
been subsequently established by two other papers [79, 80].
Unfortunately, as these trials have been carried out on very
small samples of patients, no firm conclusions can be drawn
from them.
Overall, those data represent, at best, only a promising
preliminary hint, seldom emerging from anecdotal observa-
tions. Indeed, a number of critical factors actually limit the
clinical relevance of the available results.
First, no extensive, randomized trials have been done
till now. Pilot studies are potentially flawed by the reduced
number of enrolled patients and (with some exceptions)
the lack of randomization. Well-designed clinical studies are
thereby required to evaluate, if any, the different respon-
siveness among men/women and the diverse sensitivity of
solid/hematological cancers when treated with inositol(s).
Due to the hypothetical mechanisms of inositol action, these
surveys would require an extended period of observation
and larger patient samples than those studied till now. That
remark applies also to chemopreventive studies. Even if there
are no ongoing or planned randomized clinical trials with
either InsP6 or myo-Ins, a recent clinical study promoted
by the NIH [145] showed no benefit associated with myo-
Ins supplementation in heavy smokers carrying bronchial
dysplasia. Yet, even this survey is biased by the limited
number of subjects (38 in themyo-Ins arm versus 36 placebo-
treated controls) entering the study.
Second, clinical studies should be aimed at recording not
only the response in terms of cancer changes but also the
concomitant modification in metabolic/endocrine milieu.
Indeed, an almost entirely overlooked field of investigation
is represented by the involvement of inositol(s) in estrogen
modulation. This is a potentially outstanding issue, as inos-
itol(s) have been shown to modulate aromatase activity as
well as a number of circulating hormones (including insulin,
FSH, and LH). Studies performed in women affected by
PCOS have shown that aromatase activity and the release
of gonadotropin-releasing factors (LH and FSH) and of
numerous other hormones (including insulin, prolactin, and
testosterone) are significantly modulated by inositol addi-
tion [146]. It is therefore tempting to speculate that such
mechanismmay also participate in triggering inositol-related
anticancer effects on endocrine responsive tumors (especially
breast and prostate cancer).
Third, clinical benefit ensured by the addition of InsP6
and/or myo-Ins to conventional chemotherapy may be
ascribed to indirect physiological effects rather than to a
“direct” anticancer effect. As previously outlined, both InsP6
and myo-Ins modulate a number of proinflammatory path-
ways by targeting few components of cancer stroma (fibrob-
lasts and density of the surrounding matrix). Modulation of
cancer stroma, in associationwith the inositol-based effect on
the cytoskeleton, may efficiently contribute to reframing the
functional architecture of cancer microenvironment [103],
thus leading to a plethora of unexpected consequences,
ultimately ending up into an inhibition of cancer growth.
Inositol(s) may indeed modulate the antioxidant/proox-
idant balance, as well as the patient metabolomic fingerprint
(downregulation of insulin levels, improved glucose utiliza-
tion through the oxidative cycle, and inhibition of lipogene-
sis). Such effects have been extensively recorded in nonneo-
plastic patients suffering from PCOS or metabolic diseases
[3, 147] and likely may also be effective in cancer patients.
8. Outstanding Issues
Both myo-Ins and InsP6 have been demonstrated to exert a
wide range of anticancer effects. Namely, inositols interact
with specific cancer cellular pathways, while also exerting
other valuable activities at the systemic level (enhancement
of immune function, antioxidant activity). The astonishing
complexity of their effects (Figure 1) on so different targets
allows us to consider both of them as truly “pleiotropic”
agents. Moreover, as suggested by some preliminary reports,
it cannot be discarded that InsP6 and myo-Ins may also play
a specific epigenetic role in selected gene clusters.
8.1. Epigenetic Effects. In yeast, myo-Ins displays basically a
repressing activity on a discrete number of genes [148], and
preliminary data suggest that this is also the case in humans
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Figure 1: Inositol mechanisms of action in cancer cells. Inositols (INS), including InsP6 andmyo-Ins, modulate a number of different critical
pathways. Available data suggest that the inhibition of the phosphorylation-based (P) activation of key molecular targets represents a basic
mechanism through which inositol interferes with specific biological functions, eventually ending up in delaying cell replication and in
fostering apoptosis or phenotypic differentiation. (A) Inositols inhibit pRB phosphorylation, thus fostering the pRB/E2F complexes formation
and blocking further progression along the cell cycle. (B) Phosphatidylinositol-4,5-bisphosphonate (PIP2) is metabolized to diacylglycerol
(DAG) and Ins-trisphosphate (IP3) by phospholipase-C (PLC). Moreover, PI3K catalyzes the synthesis of PIP3 from PIP2. PIP3 is required
for enabling the activation of ERK and Akt pathways. Indeed, by reducing both PI3K levels and its activity, inositols counteract the activation
of the PKC/RAS/ERK pathway. Upstream of that pathway, inositols disrupt the ligand interaction between FGF and its receptor (FGF-r)
by interfering with syndecan (Synd) activity as well as with the EGF-transduction processes involving IGF-II receptor and AP-1 complexes.
Downstream of PI3K inhibition, Akt activation through selective phosphorylation promoted by PDK andmTORC2 is severely impaired upon
inositol addition. Downregulation of both Akt and ERK leads consequently to NF-kB inhibition and reduced expression of inflammatory
markers, like COX-2 and PGE2. Inositol-induced downregulation of presenilin-1 (PS1), when associated with inhibition of the PI3K/Akt
pathway, counteracts the epithelial-mesenchymal transition (EMT), thus reducing Wnt-activation, 𝛽-catenin (𝛽-cat) translocation, Notch-
1, N-cadherin (N-cad), and SNAI1 release. Inositols interfere also directly with different cytoskeleton components by upregulating Focal
Adhesion Kinase (FAK) and E-cadherin (Ec) and decreasing Fascin (F) and Cofilin, two main components of the pseudopodia. Reduced
formation of membrane ruffling and pseudopodia, as well as inhibited release of metalloproteinases (MMPs), severely impairs both motility
and invasiveness of cancer cells. This effect is reinforced by the inositol-induced inhibition on ROCK1/2 release, as well as by the decreased
levels of phosphorylated Myosin Light Chain (MLC). Overall, these effects enable inositols to remodel F-actin (A) assembly and thus to
reshape the cytoskeleton architecture. Blue arrow indicates promoting effect; red line with bar indicates inhibitory effect.
(personal communication). Conversely, under conditions
of inositol deprivation, hundreds of genes are activated,
mainly those involved in stress response pathways [149],
PKC pathways [150], inositol and phospholipid biosynthesis
(ISYNA1 gene) [151, 152], and glucose metabolism [153]. It
is still to be investigated if the inositol-based control on
gene expression should be ascribed to methylation specific
activity or to other mechanisms. In addition, myo-Ins has
been shown to be involved in chromatin remodeling and
DNA-repair processes. Chromatin remodeling represents a
critical process ruling the access for DNA-binding proteins
and therefore it is required for efficient gene transcription.
Mutation in genes encoding inositol polyphosphate kinases
responsible for the production of InsP4, InsP5, and InsP6
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impairs gene transcription in vivo, thus evidencing that
specific inositol phosphates are required for proper transcrip-
tional activity, thus establishing a clear link between InsPs
availability and chromatin remodeling [154, 155]. Indeed,
inositol phosphates are involved in gene transduction, given
that depletion of InsP6, InsP7, and InsP8 by means of inositol
polyphosphate multikinase inhibition impairs mRNA export
from the nucleus [156]. Efficiency of gene transcription relies
on DNA stability and maintenance that is primarily ensured
by DNA-repair mechanisms. Homologous recombination
and nonhomologous end-joining are the two main DNA-
repair mechanisms frequently deregulated in a number of
pathological conditions. Inositol phosphates (mainly InsP6)
have been shown to foster DNA-repair processes by binding
to the DNA end binding protein Ku [157]. Inositol hexak-
isphosphatemodulates Ku dynamics [158] by interactingwith
a specificKu region and, by subsequently activating theDNA-
PKbinding, InsP6 promotes the nonhomologous end-joining
repair [159]. Furthermore, it has been shown that InsP6 binds
to DNA-PK and specifically stimulates DNA-PK-dependent
end-joining in vitro [158].
8.2. Synergistic Effects. There is a widespread consensus
suggesting that InsP6 and myo-Ins act synergistically when
added in association.That finding evidences a possible cumu-
lative effect on selected targets or, evenmore likely, a complex
metabolic interaction. InsP6 has indeed been demonstrated
to be dephosphorylated within the cell, leading to myo-Ins
or to less phosphorylated forms (namely, InsP5 and InsP4)
[23, 160] which, in association withmyo-Ins, may collectively
modify the network of inositol-based molecules and hence
a number of biochemical pathways. Moreover, a number of
inositol derivatives, including lower phosphorylated forms
[161, 162] and pyrophosphates [163], have been proven to exert
anticancer effects. However, despite the fact that some insight
has been provided by using [3H]InsP6 [164] or [3H]myo-Ins
[165], we are still unable to grasp what the cellular fate of
both InsP6 and myo-Ins could be after the cellular uptake.
Additionally, inositol isomers may also play a significant
biological role, hitherto evidenced in other diseases. For
example, the association of myo-Ins and D-chiro-inositol in
a proper ratio (40 : 1) has been demonstrated to be effective in
polycystic ovary syndrome treatment [166], while scyllo-Ins is
currently under scrutiny as a reliable treatment for Alzheimer
and other neurological diseases [167]. It would be worth of
interest to ascertainwhether inositol isomers or other inositol
derivatives could also exert any valuable biological effect in
cancer. It is therefore mandatory to investigate thoroughly
the inositol metabolomics in order to identify the main
metabolic pathways of both InsP6 and myo-Ins. Further-
more, metabolomics data should be integrated with genomic
pathways, thus providing the basic information required to
recognize the cellular fate of therapeutically added inositols
and the genomic/enzymatic targets downstream.
8.3. Pleiotropic Effects. Inositol and its phosphorylated deriv-
atives (InsP6 and InsP5) interfere with several critical pro-
cesses involved in the regulation of cell proliferation, apop-
tosis, and differentiation, including the MAPK-ERK cascade,
the PI3K/Akt, and the 𝛽-catenin/Wnt/NF-kB pathway. The
PI3K/Akt pathway has been proven to be inhibited by a
wide range of inositol phosphates (InsP6, InsP5, and InsP4)
[168] as well as by myo-Ins. This effect can be ascribed to
several mechanisms including direct PI3K blocking (as the
structure of InsP6 appears to be very similar to 3-deoxy-3-
fluoro-PtdIns, a potent PI3K inhibitor) [169] or inhibiting
the PI(3,4,5)P3-dependent Akt recruitment to the plasma
membrane [170].Moreover, it seems thatmyo-Ins, InsP6, and
other inositols phosphate derivativesmaymodulate cell func-
tion by inhibiting several phosphorylation pathways. Activa-
tion mechanisms through phosphorylation of Ras, mitogen-
activated protein kinases (MAPK), protein kinase C (PKC),
PI3K, and activating-protein-1 (AP-1) are indeed downregu-
lated by inositols via a direct control of protein phosphoryla-
tion. InsP6 inhibits the phosphorylation-induced activation
of ERK and JNK activity in a number of cancer types [75, 82,
171]. InsP6 selectively activates two distinct isoforms of PKC:
PKC-𝜀 and PKC-𝛿. PKC-𝜀 is required for insulin secretion
and primes Ca2+-induced exocytosis in pancreatic 𝛽-cells
upon InsP6 stimulation [172]. PKC-𝛿 activity is increased
severalfold after InsP6 addition, and that increase leads
subsequently to enhanced release of p27, thus blocking cell
cycle progression in breast cancer cells [36]. Phosphorylation
of specific residues seems to be a widely used mechanism
in nature for activating specific molecular effectors, while
dephosphorylating performed by phosphatases (like PTEN
[173], SHIP [174], or inositol polyphosphate phosphatases
[175]) represents a general inhibitory tool for counteracting
the same pathways. Therefore, the complexity of the inositol
metabolism stands out in themidst of the evenmore complex
field of enzymatic regulation and it is quite impossible to deal
with this complexity only relying on the rules provided by the
old-fashioned reductionist model. On the contrary, a systems
biology approach [176] is mandatory to efficiently grasp the
interwoven inositol network.
9. Conclusion
Myo-inositol and its derivatives, among which InsP6 occu-
pies a relevant place, have been shown to playmany biological
functions, including modulation of cell cycle progression,
apoptosis, and differentiation. During the last decade, evi-
dence is mounting that inositol acts on both cytosolic and
nuclear targets in enabling cells to successfully cope with
many different stressors. Indeed, the inositol network seems
to display a key role during developmental processes and cel-
lular differentiation, as demonstrated by studies carried out
on oocyte maturation and embryo development [177, 178].
Available results suggest that the combination InsP6+
myo-Ins may bemost effective to move forward in the future.
It can be hypothesized that this association may enact the
release of low-phosphorylated inositol derivatives (InsP5,
InsP4, InsP3, and InsP2), which in turn may trigger specific
effects. Alternatively, InsP6 and myo-Ins may target the same
molecularmechanisms or enzymatic pathway displaying true
synergistic (rather than additive) effects. However, until a
metabolomic profile of added myo-Ins will be available,
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hypotheses on the synergistic effect of InsP6 andmyo-Ins are
at best presumptive.
Cancer can be considered a kind of “development gone
awry” [179], in which the deregulation in the crosstalk
among cells and theirmicroenvironment plays a relevant role.
Given that inositol participates in the cell-stroma interplay
by modulating metalloproteinases, E-cadherin, focal kinase
complexes, and many other cytoskeletal components, it can
be hypothesized that inositol and its derivatives may counter-
act cancer-related processes by specifically acting at this level,
that is, by restoring a “normal” cell-stroma relationship. Stud-
ies in this field are therefore urgently warranted in order to
deepen our understanding of inositol mechanisms on cancer.
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